Inclusion Criteria:

          -  Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS)
             mutation in tumour tissue or blood prior to screening. Activating mutations may
             include but are not limited to: KRAS mutations in expressed region (exon) 2 (G12,
             G13), exon 3 (A59, Q61) and exon 4 (K117, A146).

          -  Provision of archival tumour tissue, if available, to confirm retrospectively KRAS
             mutation status and for biomarker assessment

          -  At least one target lesion that can be measured per Response Evaluation Criteria In
             Solid Tumours (RECIST) version 1.1. In patients who only have one target lesion, and a
             biopsy of the lesion is required, the baseline imaging must be performed at the
             earliest two weeks after the biopsy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening

          -  Adequate organ function at screening as follows:

               -  Absolute neutrophil count (ANC) ≥1.5 x 109/L; hemoglobin ≥9.0 g/dL; platelets
                  ≥100 x 109/L without the use of haematopoietic growth factors or recent
                  transfusion

               -  Total bilirubin ≤1.5 times the upper limit of normal (ULN), or ≤4 x ULN for
                  patients who are known to have Gilbert's syndrome.

               -  Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if
                  concurrent glomerular filtration rate (GFR) ≥50 mL/min (measured or calculated by
                  Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN if no
                  demonstrable liver metastases, or ≤ 5 x ULN if transaminase elevation is
                  attributable to liver metastases.

          -  Age ≥18 years of age, or over the legal age of consent as required by local
             legislation at informed consent.

          -  Recovery from any previous therapy related toxicity to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade ≤1 at Cycle 1 Day 1 (except for alopecia, stable sensory
             neuropathy must be CTCAE Grade ≤2 and except for amenorrhea/menstruation related
             disorders of any grade) before the first dose.

          -  Signed and dated written informed consent in accordance with Good Clinical Practice
             (GCP) and local legislation prior to admission to the trial.

        Further inclusion criteria apply.

        Exclusion Criteria:

          -  Previous anticancer chemotherapy or anticancer immunotherapy within 3 weeks of the
             first administration of trial drug. Previous anticancer hormonal treatment within 2
             weeks of the first administration of trial drugs.

          -  Previous treatment with Rat sarcoma (RAS), Mitogen-activated protein kinase (MAPK) or
             Son of Sevenless 1 (SOS1) targeting agents

          -  Radiotherapy within 4 weeks prior to start of treatment except as follows

               -  Palliative radiotherapy to regions other than the chest is allowed up to 2 weeks
                  prior to start of treatment

               -  Single dose palliative radiotherapy for symptomatic metastasis within 2 weeks
                  prior to start of treatment may be allowed but must be discussed with the
                  sponsor.

          -  Major surgery (major according to the investigator's assessment) performed within 4
             weeks prior to start of treatment or planned during the projected course of the trial,
             e.g. hip replacement.

          -  Previous treatment with any investigational agent(s) or targeted treatment within 28
             days prior to start of treatment.

          -  Known history of hypersensitivity to any of the excipients of BI 1701963 tablets

          -  History or presence of cardiovascular abnormalities such as uncontrolled hypertension,
             congestive heart failure New-York-Heart-Assocation (NYHA) classification of ≥3,
             unstable angina or poorly controlled arrhythmia which are considered clinically
             relevant by the investigator; myocardial infarction within 6 months prior to start of
             treatment. Uncontrolled hypertension is defined as: Blood pressure (BP) measured in a
             rested and relaxed condition, where systolic BP ≥140 mmHg, or diastolic BP ≥90 mmHg,
             with or without medication.

          -  Left ventricular ejection fraction (LVEF) <50 %. Further exclusion criteria apply.